New combo therapy targets stubborn kidney transplant rejection
NCT ID NCT02201576
First seen Feb 15, 2026 · Last updated Apr 28, 2026 · Updated 8 times
Summary
This study tested whether adding bortezomib to standard treatments (steroids, plasma exchange, and immunoglobulins) can help control chronic antibody-mediated rejection in kidney transplant recipients. 60 adults who had a kidney transplant and developed donor-specific antibodies were enrolled. The goal was to reduce signs of rejection in kidney biopsies and lower harmful antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC ANTIBODY-MEDIATED TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Necker Enfants-malades
Paris, 75015, France
Conditions
Explore the condition pages connected to this study.